



PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s)	Suthanthiran, et al.	Examiner:	Gary B. Nickol
Serial No.:	10/627,408	Group Art Unit:	1642
Confirmation No:	2823	Docket:	955-10 P/CON/DIV
Filed:	July 25, 2003	Dated:	February 21, 2006
For:	USE OF ANTIOTENSIN II INHIBITORS TO PREVENT MALIGNANCIES ASSOCIATED WITH IMMUNOSUPPRESSION		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

*I hereby certify this correspondence is being deposited  
with the United States Postal Service as first class mail,  
postpaid in an envelope, addressed to:  
Commissioner for Patents, P.O. Box 1450,  
Alexandria, Virginia 22313-1450  
on February 21, 2006*

Signed: *Gary B. Nickol*

**RESPONSE TO RESTRICTION REQUIREMENT**

Sir:

In an Office Action mailed November 22, 2005, the Examiner has imposed a  
Restriction Requirement to one of the following inventions under the provisions of 35 U.S.C.  
§121:

Group I. Claims 1-2, 4, 14, drawn to a method for reducing or preventing formation or  
metastasis of a neoplasm in a mammal comprising treating the mammal with  
an effective amount of an angiotensin II inhibitor wherein the inhibitor is an  
*angiotensin converting enzyme* (ACE) inhibitor, classified in class 424,  
subclass 184.1; class 514, subclass 1.


- Group II. Claims 1-3, 5, 12, 14 drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the inhibitor comprises an *anti-angiotensin II antibody*, classified in class 424, subclass 130.1.
- Group III. Claims 1-2, 6, 14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the inhibitor comprises an *anti-angiotensin I antibody*, classified in class 424, subclass 130.1.
- Group IV. Claims 1-2, 7, 14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the inhibitor comprises an *anti-angiotensinogen antibody*, classified in class 424, subclass 130.1.
- Group V. Claims 1-3, 8, 14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the inhibitor is a *protein or peptide*, classified in class 424, subclass 184.1.
- Group VI. Claims 1-2, 9-10, 14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the angiotensin II inhibitor is a *renin inhibitor*, classified in class 530, subclass 860.
- Group VII. Claims 1-2, 11, 14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the inhibitor *blocks expression of angiotensinogen*, classified in class 514, subclass 44.
- Group VIII. Claims 1-2, 13-14, drawn to a method for reducing or preventing formation or metastasis of a neoplasm in a mammal comprising treating the mammal with an effective amount of an angiotensin II inhibitor wherein the inhibitor is a small molecule, classified in class 514, subclass 1.

In response to the Restriction Requirement, Applicants elect the subject matter defined by the claims of Group VIII (claims 1-2 and 13-14), without traverse.

Applicants reserve the right to pursue the claims of the non-elected Groups in divisional applications.

It is now believed that this application is in condition for further consideration and examination. If resolution of any remaining issues are required prior to examination of the application, it is respectfully requested that the Examiner contact Applicants' agent at the telephone number provided below.

Respectfully submitted,

  
Edna I. Gergel, Ph.D.  
Registration No.: 50,819  
Agent for Applicant(s)

HOFFMANN & BARON, LLP  
6900 Jericho Turnpike  
Syosset, New York 11791  
(516) 822-3550  
EIG:sbs

217452\_1